- Home
- PDO vs SDGR Comparison
PDO vs SDGR Comparison
Compare PDO & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PDO
- SDGR
- Stock Information
- Founded
- PDO 2020
- SDGR 1990
- Country
- PDO United States
- SDGR United States
- Employees
- PDO N/A
- SDGR N/A
- Industry
- PDO Trusts Except Educational Religious and Charitable
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- PDO Finance
- SDGR Health Care
- Exchange
- PDO Nasdaq
- SDGR Nasdaq
- Market Cap
- PDO 1.6B
- SDGR 1.6B
- IPO Year
- PDO N/A
- SDGR 2020
- Fundamental
- Price
- PDO $13.36
- SDGR $22.04
- Analyst Decision
- PDO
- SDGR Buy
- Analyst Count
- PDO 0
- SDGR 10
- Target Price
- PDO N/A
- SDGR $32.90
- AVG Volume (30 Days)
- PDO 520.0K
- SDGR 594.0K
- Earning Date
- PDO 01-01-0001
- SDGR 11-12-2024
- Dividend Yield
- PDO 11.80%
- SDGR N/A
- EPS Growth
- PDO N/A
- SDGR N/A
- EPS
- PDO N/A
- SDGR N/A
- Revenue
- PDO N/A
- SDGR $193,348,000.00
- Revenue This Year
- PDO N/A
- SDGR N/A
- Revenue Next Year
- PDO N/A
- SDGR $26.50
- P/E Ratio
- PDO N/A
- SDGR N/A
- Revenue Growth
- PDO N/A
- SDGR N/A
- 52 Week Low
- PDO $10.65
- SDGR $16.67
- 52 Week High
- PDO $13.31
- SDGR $38.00
- Technical
- Relative Strength Index (RSI)
- PDO 39.06
- SDGR 53.17
- Support Level
- PDO $13.35
- SDGR $20.33
- Resistance Level
- PDO $13.90
- SDGR $21.96
- Average True Range (ATR)
- PDO 0.09
- SDGR 0.97
- MACD
- PDO -0.03
- SDGR -0.15
- Stochastic Oscillator
- PDO 14.68
- SDGR 42.80
About PDO PIMCO Dynamic Income Opportunities Fund of Beneficial Interest
PIMCO Dynamic Income Opportunities Fund is a closed-end management investment company. The fund's primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.